FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2622726242> ?p ?o ?g. }

• W2622726242 abstract "e12038 Background: The Breast-DX Italy prospective study evaluated the impact of the 21-gene RS on adjuvant treatment decisions for early BC patients. Methods: The study was conducted in 9 centers of the Veneto Region (2 hub and 7 spoke). All consecutive patients with ER+/HER2-, T1 to T3, N0 to N1 early BC who met protocol-defined clinicopathological criteria for “intermediate risk” were included. Pre-RS and post-RS physicians’ treatment recommendations and treatment actually received were collected. Results: From November 2014 to August 2016, n=124 N0 and n=126 N1 patients were enrolled (65% at hub and 35% at spoke centers). The majority had PgR+ (86%), G2 (71%) and pT1c (63%) BC. Median age was 55 yrs, median Ki67 was 20% (range 2-70%). The distribution of RS was: <18 (61%), 18-30 (32%) and >30 (7%). Main factors associated with higher RS were G3 and higher ki67. The addition of chemotherapy (CT) to hormonal therapy (HT) was initially recommended for 48% of the patients (38% of N0 and 57% of N1 patients; 54% and 37% of patients enrolled at hub and spoke centers, respectively). The post-RS recommendation changed from the pre-RS recommendation for 40 patients, mostly from CT+HT to HT (n=30; n=25 with low and n=5 with intermediate RS). Change was more frequent for N1 patients (Table). Of the 72 N1 patients initially recommended to CT+HT, 28% had a post-RS indication to HT alone. The crude number of patients with pre-RS recommendation to CT significantly exceeded the number of patients who finally received it (absolute difference =31; p<0.001). The majority of CT treatments were spared at hub vs spoke centers (n=24 and n=7, respectively). Conclusions: Pre-RS indication to HT alone was frequent, in particular for N0 patients and at spoke centers. The use of the 21-gene RS further contributed in sparing CT administration, more so for N1 patients and at hub centers. The impact of the RS when used at discretion of the clinicians is currently under investigation in the prospective ROXANE study. [Table: see text]" @default.
• W2622726242 created "2017-06-15" @default.
• W2622726242 creator A5028218642 @default.
• W2622726242 creator A5030048731 @default.
• W2622726242 creator A5031348432 @default.
• W2622726242 creator A5034632931 @default.
• W2622726242 creator A5037416860 @default.
• W2622726242 creator A5039426761 @default.
• W2622726242 creator A5039840531 @default.
• W2622726242 creator A5040666234 @default.
• W2622726242 creator A5050215401 @default.
• W2622726242 creator A5055333835 @default.
• W2622726242 creator A5067254806 @default.
• W2622726242 creator A5068906915 @default.
• W2622726242 creator A5073539838 @default.
• W2622726242 creator A5074457501 @default.
• W2622726242 creator A5074726037 @default.
• W2622726242 creator A5085165482 @default.
• W2622726242 date "2017-05-20" @default.
• W2622726242 modified "2023-09-28" @default.
• W2622726242 title "First prospective multicenter Italian study on the impact of the 21-Gene Recurrence Score (RS) in adjuvant clinical decisions for ER+/HER2- early breast cancer (BC) patients." @default.
• W2622726242 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e12038" @default.
• W2622726242 hasPublicationYear "2017" @default.
• W2622726242 type Work @default.
• W2622726242 sameAs 2622726242 @default.
• W2622726242 citedByCount "0" @default.
• W2622726242 crossrefType "journal-article" @default.
• W2622726242 hasAuthorship W2622726242A5028218642 @default.
• W2622726242 hasAuthorship W2622726242A5030048731 @default.
• W2622726242 hasAuthorship W2622726242A5031348432 @default.
• W2622726242 hasAuthorship W2622726242A5034632931 @default.
• W2622726242 hasAuthorship W2622726242A5037416860 @default.
• W2622726242 hasAuthorship W2622726242A5039426761 @default.
• W2622726242 hasAuthorship W2622726242A5039840531 @default.
• W2622726242 hasAuthorship W2622726242A5040666234 @default.
• W2622726242 hasAuthorship W2622726242A5050215401 @default.
• W2622726242 hasAuthorship W2622726242A5055333835 @default.
• W2622726242 hasAuthorship W2622726242A5067254806 @default.
• W2622726242 hasAuthorship W2622726242A5068906915 @default.
• W2622726242 hasAuthorship W2622726242A5073539838 @default.
• W2622726242 hasAuthorship W2622726242A5074457501 @default.
• W2622726242 hasAuthorship W2622726242A5074726037 @default.
• W2622726242 hasAuthorship W2622726242A5085165482 @default.
• W2622726242 hasConcept C121608353 @default.
• W2622726242 hasConcept C126322002 @default.
• W2622726242 hasConcept C143998085 @default.
• W2622726242 hasConcept C168563851 @default.
• W2622726242 hasConcept C188816634 @default.
• W2622726242 hasConcept C2777863537 @default.
• W2622726242 hasConcept C29456083 @default.
• W2622726242 hasConcept C2992435398 @default.
• W2622726242 hasConcept C530470458 @default.
• W2622726242 hasConcept C71924100 @default.
• W2622726242 hasConceptScore W2622726242C121608353 @default.
• W2622726242 hasConceptScore W2622726242C126322002 @default.
• W2622726242 hasConceptScore W2622726242C143998085 @default.
• W2622726242 hasConceptScore W2622726242C168563851 @default.
• W2622726242 hasConceptScore W2622726242C188816634 @default.
• W2622726242 hasConceptScore W2622726242C2777863537 @default.
• W2622726242 hasConceptScore W2622726242C29456083 @default.
• W2622726242 hasConceptScore W2622726242C2992435398 @default.
• W2622726242 hasConceptScore W2622726242C530470458 @default.
• W2622726242 hasConceptScore W2622726242C71924100 @default.
• W2622726242 hasLocation W26227262421 @default.
• W2622726242 hasOpenAccess W2622726242 @default.
• W2622726242 hasPrimaryLocation W26227262421 @default.
• W2622726242 isParatext "false" @default.
• W2622726242 isRetracted "false" @default.
• W2622726242 magId "2622726242" @default.
• W2622726242 workType "article" @default.